BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35605533)

  • 1. County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019.
    Corry B; Underwood N; Cremer LJ; Rooks-Peck CR; Jones C
    Drug Alcohol Depend; 2022 Jul; 236():109495. PubMed ID: 35605533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
    Krawczyk N; Jent V; Hadland SE; Cerdá M
    J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes In County-Level Access To Medications For Opioid Use Disorder After Medicare Coverage Of Methadone Treatment Began.
    Harris SJ; Yarbrough CR; Abraham AJ
    Health Aff (Millwood); 2023 Jul; 42(7):991-996. PubMed ID: 37406230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
    Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.
    Benck KN; Seide K; Jones AK; Omori M; Rubinstein LB; Beckwith C; Nowotny KM
    Drug Alcohol Depend; 2023 Jun; 247():109863. PubMed ID: 37071946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
    Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
    Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
    [No Abstract]   [Full Text] [Related]  

  • 8. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
    Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
    JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
    Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities.
    Rizk JG; Saini J; Kim K; Pathan U; Qato DM
    PLoS One; 2024; 19(4):e0301863. PubMed ID: 38578818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years.
    Abraham AJ; Harris SJ; Yarbrough CR
    J Subst Use Addict Treat; 2024 Mar; 158():209247. PubMed ID: 38072386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.
    Stein BD; Dick AW; Sorbero M; Gordon AJ; Burns RM; Leslie DL; Pacula RL
    Subst Abus; 2018; 39(4):419-425. PubMed ID: 29932847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
    Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs.
    Tsui JI; Whitney BM; Korthuis PT; Chan B; Pho MT; Jenkins WD; Young AM; Cooper HLF; Friedmann PD; Stopka TJ; de Gijsel D; Miller WC; Go VF; Westergaard R; Brown R; Seal DW; Zule WA; Feinberg J; Smith GS; Mixson LS; Fredericksen R; Crane HM; Delaney JA;
    Drug Alcohol Depend; 2023 Sep; 250():110911. PubMed ID: 37549545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
    Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
    J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
    Shastry S; Nobel I; Allen LR; Richardson LD; Vidal K; Manini AF
    Am J Emerg Med; 2022 Jan; 51():114-118. PubMed ID: 34735968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.
    Dickson-Gomez J; Krechel S; Ohlrich J; Montaque HDG; Weeks M; Li J; Havens J; Spector A
    Harm Reduct J; 2024 Feb; 21(1):52. PubMed ID: 38413972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
    Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.